SPARC Stock Overview
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Sun Pharma Advanced Research Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹332.55 |
| 52 Week High | ₹472.80 |
| 52 Week Low | ₹178.80 |
| Beta | 0.74 |
| 1 Month Change | -5.74% |
| 3 Month Change | -13.36% |
| 1 Year Change | 71.15% |
| 3 Year Change | 89.33% |
| 5 Year Change | 90.85% |
| Change since IPO | 281.36% |
Recent News & Updates
Sun Pharma Advanced Research (NSE:SPARC) Is In A Good Position To Deliver On Growth Plans
Jan 17
Sun Pharma Advanced Research Company Limited's (NSE:SPARC) Business Is Trailing The Industry But Its Shares Aren't
Nov 14Recent updates
Sun Pharma Advanced Research (NSE:SPARC) Is In A Good Position To Deliver On Growth Plans
Jan 17Sun Pharma Advanced Research Company Limited's (NSE:SPARC) Business Is Trailing The Industry But Its Shares Aren't
Nov 14Is Sun Pharma Advanced Research (NSE:SPARC) Using Too Much Debt?
Sep 05Here's Why We're Not At All Concerned With Sun Pharma Advanced Research's (NSE:SPARC) Cash Burn Situation
Jun 27Is Sun Pharma Advanced Research (NSE:SPARC) A Risky Investment?
Nov 23If You Had Bought Sun Pharma Advanced Research's (NSE:SPARC) Shares Three Years Ago You Would Be Down 57%
Feb 08
Do Institutions Own Sun Pharma Advanced Research Company Limited (NSE:SPARC) Shares?
Dec 14Shareholder Returns
| SPARC | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -18.5% | -2.5% | -2.5% |
| 1Y | 71.2% | 55.2% | 44.5% |
Return vs Industry: SPARC exceeded the Indian Pharmaceuticals industry which returned 55.2% over the past year.
Return vs Market: SPARC exceeded the Indian Market which returned 44.5% over the past year.
Price Volatility
| SPARC volatility | |
|---|---|
| SPARC Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: SPARC's share price has been volatile over the past 3 months.
Volatility Over Time: SPARC's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 407 | Anilkumar Raghavan | www.sparc.life |
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, dermatology, and Immunology. The company offers Elepsia XR, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension; and Phenobarbital injection for the treatment of neonatal seizures.
Sun Pharma Advanced Research Company Limited Fundamentals Summary
| SPARC fundamental statistics | |
|---|---|
| Market cap | ₹113.60b |
| Earnings (TTM) | -₹3.63b |
| Revenue (TTM) | ₹1.07b |
101.2x
P/S Ratio-29.7x
P/E RatioIs SPARC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPARC income statement (TTM) | |
|---|---|
| Revenue | ₹1.07b |
| Cost of Revenue | ₹326.64m |
| Gross Profit | ₹740.16m |
| Other Expenses | ₹4.37b |
| Earnings | -₹3.63b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.20 |
| Gross Margin | 69.38% |
| Net Profit Margin | -340.66% |
| Debt/Equity Ratio | 4.3% |
How did SPARC perform over the long term?
See historical performance and comparison